MDACC Study No:2007-0088 ( NCT No: NCT00405587)
Title:A Study To Assess Safety, Pharmacokinetics, and Pharmacodynamics of PLX4032 in Patients with Solid Tumors
Principal Investigator:Michael Davies
Treatment Agent:PLX-4032
Study Status:Closed
Study Description:The goals of this clinical research study are find the highest tolerable dose
of PLX4032 that can be given to patients with cancer of the colon or rectum,
learn the safety of the study drug, and perform pharmacokinetic (PK) testing of
the drug. PK testing measures the amount of a drug in the body at different
time points.
Hide details for General InformationGeneral Information

Disease Group:Colorectum; Melanoma
Phase of Study:Phase I
Treatment Agents:PLX-4032
Treatment Location:Both at MDACC & outside MDACC at one or more Collaborating Sites or Institutions
Estimated Length of Stay in Houston:N/A
Supported By:Roche, 340 Kingsland Street, Nutley, New Jersey, USA: Linda Burdette, Ph.D. Phone 973-235-4578; Fax: 973-562-3700
Return Visit:Days 1, 2 8, 15, 16 and 29 and every 4 weeks afterwards
Home Care:N/A

Hide details for Study Contact InformationStudy Contact Information

Physician Name:Michael Davies
Dept:Melanoma Medical Oncology
For Clinical Trial Enrollment:713-792-2921
For General Questions about Clinical Trials:800-392-1611 (in U.S.A.) 713-792-6161 (outside U.S.A.)

Show details for Study Objectives / OutcomesStudy Objectives / Outcomes
Show details for Study Status InformationStudy Status Information
Show details for Enrollment EligibilityEnrollment Eligibility
Show details for Resources and LinksResources and Links
Show details for ResultsResults